Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HYSR part of a Megatrend
Osaka team develops new solar-to-hydrogen catalyst that uses broader spectrum of light
26 June 2017
A team at Osaka University in Japan has developed a new material based on gold and black phosphorus to harvest a broader spectrum of sunlight for water-splitting to produce hydrogen.
The three-part composite maximizes both absorbing light and its efficiency for water splitting. The core is a traditional semiconductor—lanthanum titanium oxide (LTO). The LTO surface is partly coated with gold nanoparticles. Finally, the gold-covered LTO is mixed with ultrathin sheets of the element black phosphorus (BP), which acts as a light absorber. The optimum H2 production rates of BP-Au/LTO were about 0.74 and 0.30 mmol g-1 h-1 at wavelengths longer than 420 nm and 780 nm, respectively. A paper on the team’s work is published in the journal Angewandte Chemie: International Edition.
Although H2 can be produced from direct splitting of water using semiconductor photocatalysts under solar light irradiation, the present energy conversion efficiency of STH [solar-to-hydrogen] is too low for the technology to be economically sound. The main barriers are the rapid charge recombination as well as no absorption of traditional semiconductors such as TiO2 in the visible and near-infrared (NIR) light regions.
… One of the options for extending absorption of traditional semiconductors from the UV to visible light region is hybridization with plasmonic metal nanostructures. Plasmonic photocatalysts, recently and rapidly developed novel visible-light-driven photocatalytic systems, possess great potential for improving many intrinsic limitations of conventional photocatalysts using surface plasmon resonance (SPR) properties. Since gold nanoparticles (Au NPs) generally exhibit strong SPR absorption in the visible light region, they have been used most widely.
… More recently, with adjustable band gap from 0.3 eV for bulk to 2.1 eV for monolayer, 2D black phosphorus (BP) has attracted great interest in optical and electronic applications. The band gap properties are promising because of broad solar light absorption from UV to NIR region. Herein, a ternary BP-sensitized Au/LTO (BP-Au/LTO) nanostructure was synthesized firstly and used as an efficient and stable visible and NIR-light-driven photocatalyst for H2 production.
—Zhu et al.
The team attributed the enhanced photocatalytic activity to the efficient electron transfer from BP and Au to LTO.
BP is a wonderful material for solar applications, because we can tune the frequency of light just by varying its thickness, from ultrathin to bulk. This allows our new material to absorb visible and even near infrared light, which we could never achieve with LTO alone.
—team leader Tetsuro Majima
By absorbing this broad sweep of energy, BP is stimulated to release electrons, which are then conducted to the gold nanoparticles coating the LTO. Gold nanoparticles also absorb visible light, causing some of its own electrons to be jolted out. The free electrons in both BP and gold nanoparticles are then transferred into the LTO semiconductor, where they act as an electric current for water splitting.
Hydrogen production using this material is enhanced not only by the broader spectrum of light absorption, but by the more efficient electron conduction, caused by the unique interface between two dimensional materials of BP and LTO. As a result, the material is 60 times more active than pure LTO.
Resources
•Zhu M, Cai X, Fujitsuka M, Zhang J, Majima T (2017) “Au/La2Ti2O7 Nanostructures Sensitized with Black Phosphorus for Plasmon-Enhanced Photocatalytic Hydrogen Production in Visible and Near-Infrared Light” Angewandte Chemie International Edition 56 doi: 10.1002/anie.201612315
http://www.greencarcongress.com/2017/06/20170626-osaka.html#more
boooom
first prototype of HYSR's technology out
http://www.globenewswire.com/news-release/2017/07/11/1042317/0/en/HyperSolar-Demonstrates-Large-Solar-Hydrogen-Prototype.html
NOVN Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
July 07, 2017 09:05 ET | Source: Novan, Inc.
MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational once-daily, topical monotherapy for the treatment of acne vulgaris, will be presented at the 13th World Congress of Pediatric Dermatology in Chicago, Illinois. New data from a post-hoc analysis of Novan’s recently completed Phase 3 pivotal trials, conducted in a subset of only adolescent subjects, showed a statistically significant reduction (p<0.05) in inflammatory, non-inflammatory and total lesion reductions with SB204 4% compared to vehicle, while maintaining a favorable safety and tolerability profile.
In two replicate, multi-center, randomized, double-blinded, vehicle-controlled, parallel group trials, a total of 2,639 patients ages 9 and older with moderate to severe acne were enrolled across 110 sites in the United States. In a post-hoc analysis of a subset of 905 adolescents ranging from ages 9 to under 17 years old, treated topically with SB204 Gel 4% once-daily (n=439) or vehicle gel once-daily (n=466) for 12 weeks, the Company found the following results (last observation carry forward methodology used for missing data).
•The percent change from baseline in the number of non-inflammatory lesions was -33.4% for SB204 and -24.2% for vehicle (p=0.0013).
•The percent change from baseline in the number of inflammatory lesions was -43.4% for SB204 and -36.4% for vehicle (p=0.0113).
•The percent change from baseline in the number of total lesions was -37.4% for SB204 and -29.1% for vehicle (p<0.001).
In addition, a pharmacokinetic trial in adolescents with moderate to severe acne assessed systemic exposure following topical application of SB204. No systemic exposure to markers for nitric oxide exposure under maximal use conditions was detected.
“It is encouraging to see a potential new therapy, with positive data, in development for the treatment of acne in adolescents,” said Diane Thiboutot, M.D., practicing dermatologist at The Milton S. Hersey Medical Center in Hersey, PA and professor of Dermatology at the Pennsylvania State University College of Medicine. “Acne is one of the most common skin conditions in children and teenagers, and its reach is far beyond the physical effects of the disease, extending to anxiety, depression and low self-esteem. A therapy that safely addresses the acne lesions without bothersome side effects is an unmet need for physicians, patients and parents.”
These data in an adolescent population follow the recent presentation of new findings into the potential mechanism of action of SB204 at the Dermatology Summer Symposium of the Alabama Dermatology Society in Sandestin, Florida on June 23, 2017.
In an ex-vivo human skin model designed to assess the anti-inflammatory effects of topical treatments against a toll-like receptor-stimulated overexpression of cytokines in healthy, human skin biopsies, Novan observed that a single application of SB204 4% significantly inhibited the upregulation of IL-1ß by approximately 62% as compared to untreated controls (n of 6 donors, p=0.045). IL-1ß is an inflammatory cytokine known to be involved in the pathogenesis of acne, with a fifty-fold increased presence in papulopustular acne lesions versus normal human skin.1 These findings support the hypothesis that the mechanism of anti-inflammatory effect of nitric oxide in acne prone skin is mediated by the inactivation of the NLRP3 inflammasome previously reported by Friedman and co-workers.2
Novan intends to request a follow up meeting with the U.S. Food and Drug Administration (“FDA”) in the third quarter of 2017 to discuss the path forward for the development of SB204 for the treatment of acne from both a clinical and regulatory perspective.
About the Posters
13th World Congress of Pediatric Dermatology
Title: “Pharmacokinetics and Safety of Nitric Oxide-Releasing SB204 Gel in Adolescents with Acne Vulgaris”
Authors: D Thiboutot, A Zaenglein, A Hebert, L Eichenfield
Abstract Number: LP-006
Presenter: Andrea Zaenglein, M.D.
Date and Time: Friday, July 7, 2017, 5:30 pm am – 1:30 p.m. Central Time
Dermatology Summer Symposium of the Alabama Dermatology Society
Title: “Effects of SB204 on LPS-induced Cytokine Release in an Ex-Vivo Human Skin Model”
Authors: K McHale, N Stasko and S Hollenbach
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.Novan.com.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, pharmaceutical development of nitric oxide-releasing product candidates and future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research or trials; the lengthy and unpredictable nature of the U.S. Food and Drug Administration’s drug approval process, including the risk that the FDA is not amenable to our plan for SB204 or requires additional studies or information before we can submit our NDA, the risks that we are delayed in making an NDA submission, the FDA does not accept our submission for filing, disagrees with our analysis of endpoints or that the FDA requires additional studies to support the submission and the risk the FDA does not approve our NDA or approves our NDA with limitations or subject to additional studies; whether we will be able to obtain additional funding when needed; and other risks and uncertainties described in our annual report filed with the Securities and Exchange Commission, or SEC, on Form 10-K for the twelve months ended Dec. 31, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
CONTACT: (Investors) Novan, Inc. 919-627-6847 investors@novan.com (Media) Deb Holliday Pascale Communications, LLC 412-877-4519 deb@pascalecommunications.com
http://www.globenewswire.com/news-release/2017/07/07/1041434/0/en/Novan-to-Present-Safety-and-Efficacy-Data-for-SB204-Program-in-Adolescents-at-13th-World-Congress-of-Pediatric-Dermatology.html
CLSN ~~115%~~traded in 40min 3$ comin
CLSN ~~100%~~ in 35min
CLSN ~75%~ of o/s 4.1m traded in 30min
CLSN ~75%~ of o/s 4.1m traded in 30min
CLSN ~~75%~~ of o/s 4.1m shares traded in first 20 minutes
mcap and o/s so low - nice play to come just started
huge pre volumen - awesome
GEVO lookin good
Trump Administration good for GEVO - latest News
http://energy.agwired.com/2017/06/28/rfa-leader-talks-trade-during-unica-ethanol-summit/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DomesticFuel+%28Domestic+Fuel%29
http://energy.agwired.com/2017/06/22/trumps-comments-please-ethanol-industry/
what if grants will be assigned?
*** HYSR watch out big volume in ***
If Big Oil Drowns Trump, Green Energy Could Cast Him A Lifeline
http://www.forbes.com/sites/kensilverstein/2017/01/16/if-big-oil-drowns-trump-green-energy-could-cast-him-a-lifeline/#3e11b4c23e8a
In this Jan. 13, 2017, photo, President-elect Donald Trump speaks with reporters in the lobby of Trump Tower in New York. Trump’s meetings this week with CEOs seeking federal approval for major mergers are raising red flags for ethics lawyers concerned that about the possible erosion of a firewall between the regulators tasked with approving the billion-dollar deals and the White House. (AP Photo/Evan Vucci)
As President-elect Donald Trump plans to take the oath of office on Friday January 20, he will be coming to Washington with a cloud over his head. Some are questioning his legitimacy — not just to his victory in the Electoral College but also with respect to the energy policies that he has been espousing.
The natural extension of a vitriolic campaign has undoubtedly led to the acrimony now present in the political atmosphere — a raw sentiment targeted right at Trump. That feeling will assuredly impede whatever agenda the president-elect has in mind, including his aggressive ideas aimed at lessening the nation’s use of renewables and limiting the U.S. role in mitigating climate change.
President Obama has implored the President-elect to think more broadly and to not succumb to the loudest voices representing the traditional energy sources: Businesses such as General Motors, Hewlett Packard and Johnson &Johnson are prospering both financially and environmentally from green investments.
At the same time, energy gurus like T. Boone Pickens are weighing in, advising Trump not to turn his back on new energies. While Pickens knows that oil and gas will remain lynchpins of the American economy, he has essentially told the president-elect to steer the middle ground. In a previous talk with this writer, he said that natural gas is a critical pathway to carbon reductions and that the country ought to export hydraulic fracturing technologies while also working to grow its domestic green industry— positions similar to those of Obama.
“The United States is showing that [greenhouse gas] mitigation need not conflict with economic growth,” the president wrote in the journal Science. “Rather, it can boost efficiency, productivity, and innovation. Businesses are coming to the conclusion that reducing emissions is not just good for the environment — it can also boost bottom lines, cut costs for consumers, and deliver returns for shareholders.”
Indeed, the International Energy Agency in Paris found that the world’s emissions remained flat in 2014 and 2015 even as GDP continued to grow by more than 3% in each year. In this country, more than 24,000 megawatts were added to the grid in 2016, notes the U.S. Energy Information Administration. Half that — for three years running — has been wind and solar energies.
Money to Spend
On a practical level, the Department of Energy has about $40 billion left in its loan kitty. While renewable generation has been the primary beneficiary of those loans, the money could go to other things such as advanced coal technologies. So far, the program has loaned about $22 billion while collecting $3.5 billion in repayments and $810 million in interest. Defaults have amounted to about $750 million, which has been mostly attributed to Solyndra that lost $535 million.
“We invested in a solar company, our country,” Trump said during a debate with Hillary Clinton. “That was a disaster. They lost plenty of money on that one. … Now, look, I’m a great believer in all forms of energy, but we’re putting a lot of people out of work. Our energy policies are a disaster.”
If Trump genuinely believes the current energy policies are a failure, he will follow through on his pledge to kill this country’s efforts to cut carbon emissions by trying to invalidate the Clean Power Plan and by withdrawing from the global climate accords. To that end, the president-elect has culled from the ranks of climate skeptics and tapped into the Institute for Energy Research, whose executive director Thomas Pyle has been helping to form the new Energy Department.
A story in the Los Angeles Times says that Pyle tried to stop federal involvement in such energy projects as Ivanpah, which is a 392-megawatt concentrated solar energy project that is delivering power to PG&E Corp. and Edison International. It is a joint venture among NRG Energy, Google and Brightsource Energy. The deal relied heavily on Energy Department funding — monies that Pyle’s group thinks of as wasted on a boondoggle project.
Meanwhile, the same LA Times story says that the institute has repeatedly referenced a study that has been proven faulty and one that looks at Spain’s experience with renewables: For every one green energy job gained, the institute says that two other jobs are lost. The Spanish government continues to protest that characterization while it points out the fallacies of its evaluation.
Meantime, Trump’s pick to head the Environmental Protection Agency is already one of the agency’s leading antagonists and he also questions the validity of the prevailing climate science. He is suing to stop any advancement of the Clean Power Plan while also doing the same regarding the Obama administration’s plans to curb methane releases from oil and gas drilling. If approved by the Senate, Scott Pruitt’s EPA could weaken the regulatory environment by acts of omission, or simply refusing to defend regulations in court.
“The Obama Climate Action Plan is about restricting access to America’s vast resources of coal and natural gas, which together supply approximately two-thirds of our nation’s affordable electricity,” Pyle has previously said. Economic progress is paramount here, he emphasizes.
Defining the Threat
But even the oil companies that Pyle’s group represents are diversifying their holdings and expanding into renewables and green technologies. Part of that is because oil prices are low and part is because of the pressures they are getting from environmentalists. But those companies would not buck the interest of their shareholders if they didn’t think the investments would pay off.
Consider that Total of France has already spent $1.4 billion buying SunPower while it said in 2016 it would buy battery maker Saft for $1 billion. Royal Dutch Shell, meantime, has formed Shell New Energies that will invest $200 million a year on green technologies. And ExxonMobil Corp. also said last year that it would explore carbon capture and sequestration with a fuel cell company.
To that end, President-elect Trump’s pick to head the US Department of State said that the United States should stay involved in the Paris climate accord. As the former chief executive of Exxon, Rex Tillerson has come around and said that fossil fuels contribute to man-made climate change, although he did tell Congress last week that trying to tackle the issue unilaterally would put the nation at an economic disadvantage.
“No one country is going to solve this alone,” Tillerson testified. “I think we’re better served by being at the table than leaving the table,” referring to the global climate accord signed in December 2015 in Paris.
On the surface, it would appear that Trump has boxed himself in and taken hardline positions counter to those that have gained traction under President Obama. But behind the scenes, some of those advising him are telling him not to block such progress — including members of his own party, whose states have benefited from the New Energy Economy.
His positions change daily. But the political framework is now established, which is that Trump lost the popular election by 3 million votes and that many Americans view him as a threat to democracy. Maintaining rigid positions will only further alienate him, meaning that he must curb the inflammatory rhetoric or else see further aspersions cast on his legitimacy.
Energy projects on Trump's "Priority List" could add 9 gigawatts of clean power.
http://www.forbes.com/sites/christopherhelman/2017/01/27/green-energy-features-big-in-trumps-top-50-infrastructure-projects/#707f75724503
A list emerged this week; it appears to have been prepared for then President-elect Trump, and is titled: “Priority List: Emergency & National Security Projects.” It’s 50 pages for 50 infrastructure projects — quick facts on a host of highways, bridges, powerlines and airports, the construction of which would naturally make America greater, cost $140 billion, and require enough engineering and construction work to keep the equivalent of 24,000 people employed for 10 years.
Surprisingly, the list contains no mention of a Great Wall on the Mexico border, nor the Keystone XL or Dakota Access pipeline projects. The one pipeline project on the list is the Atlantic Coast Pipeline, which would move natural gas from Pennsylvania’s Marcellus shale down to the Southeast. Owned by Dominion Resources, Duke Energy and Southern Company, the pipeline would cost about $5 billion and provide 10,000 job years.
The rest of the energy infrastructure projects are surprisingly green and may give a glimmer of hope to renewable energy fans worried about the potential for Trump to roll back the Clean Power Plan and promote coal and oil over the likes of wind and solar.
Project #9. The $2.5 billion, Plains and Eastern Electric Transmission Lines, which would carry 4 gigawatts of Oklahoma wind power 700 miles to the southeast via direct current. Developed by Clean Line Energy Partners (CFO Dave Berry appeared on the 2012 Forbes 30 Under 30 list).
Project #16. TransWest Express, a $3 billion 3-gigawatt line, backed by billionaire Phil Anschutz, which would move power from a Wyoming wind farm to Arizona, California and Nevada. The project is deep into the permitting process. Would provide 3,000 jobs.
Project #17. That Wyoming wind farm, to be built on is called Chokecherry & Sierra Madre Wind Energy. Plans call for 1,000 wind turbines, at a cost of $5 billion. The Bureau of Land Management this month approved the first 500 windmills. Generates 1,000 jobs.
time for change
whatever rumours__got on short before close yesterday__squeezin&absolutely oversold
VITAROS® EFFICACY AND SAFETY IN VIAGRA® NON-RESPONDERS WITH LONGER TERM USE
https://www.auanet.org/university/abstract_detail.cfm?id=1519&meetingID=13SAN
Abstract: 1519
Date & Time: May 7, 2013 08:00 AM
Session Title: Sexual Function/Dysfunction/Andrology:Medical and Non-surgical Therapy
Sources of Funding: Private Industry
Introduction and Objectives
Vitaros® (alprostadil topical cream) is a novel erectogenic therapy, applied topically to the urethral meatus. The efficacy and safety of Vitaros®, was tested in erectile dysfunction (ED) patients in Phase 3 clinical trials including men who had previously taken the phosphodiesterase type 5 (PDE-5) inhibitor, Viagra®. Efficacy after twelve weeks and longer term use was evaluated to determine whether Vitaros® may sustain erectile function in men previously unresponsive to PDE-5 inhibitors.
Methods
Initially, a twelve-week trial treated 1732 patients with placebo or three dose levels of Vitaros (100, 200, 300 mcg). Of these, 325 patients had a history of Viagra® use but discontinued due to no or low efficacy. Patients completed the international index of erectile function (IIEF) at multiple time points. Subsequently, an open-label flexible dose trial (planned for twelve months) enrolled the same patients to assess longer-term safety and efficacy. Patients were given eight doses of Vitaros® 200 mcg dose and then permitted to choose their dose for the remainder of the study. Of the 325 Viagra-failure patients, >70% continued in the open label trial. The IIEF erectile function (EF) domain score was compared between baseline and after twelve weeks of treatment and the patient’s last visit in the open-label trial. Safety was evaluated in patients receiving at least one dose.
Results
After twelve weeks, the mean change in IIEF EF domain score was greater for the treatment groups (ranging from 1.2-1.6 as compared to placebo (–0.9). This increase in the IIEF-EF was enhanced with longer treatment in the open-label trial. The dose most commonly chosen by the patients was 300 mcg. Although individual variability occurred, the IIEF-EF tended to increase with time, especially in those patients with IIEF-EF scores >10. The adverse events reported in this subset of patients were mild to moderate local reactions not markedly different from the overall trend in the remaining safety population. Additionally, the incidence of AE reports decreased with repeated exposure.
Conclusions
In general, Vitaros® 200 and 300 mcg doses showed improved erections in this population and adverse events were limited, decreasing with repeated exposure. Therefore, Vitaros® may be a viable treatment option for those patients previously unresponsive to PDE-5 inhibitors.
Authors
Mulhall, John (New York, NY); Buvat, Jacques; Goldstein, Irwin; Damaj, Bassam; Frank, Daniel; Fernando, Ysabella
squeeeeeezin today
groundbreakin News__pre-RS last closing .193__only 7m OS__boom
$~$__GEVO EPA Approves Pathway for Isobutanol as an Advanced Biofuel__$~$
Date : 01/17/2017 @ 9:00AM
Source : GlobeNewswire Inc.
Stock : Gevo, Inc. (MM) (GEVO)
Quote : 3.72 0.0 (0.00%) @ 9:06AM
http://ih.advfn.com/p.php?pid=nmona&article=73628785&symbol=GEVO
$~$__GEVO EPA Approves Pathway for Isobutanol as an Advanced Biofuel__$~$
Date : 01/17/2017 @ 9:00AM
Source : GlobeNewswire Inc.
Stock : Gevo, Inc. (MM) (GEVO)
Quote : 3.72 0.0 (0.00%) @ 9:06AM
http://ih.advfn.com/p.php?pid=nmona&article=73628785&symbol=GEVO
DRYS bouncin nOw
! DRYS nOw bouncin !
missed VDRM- try super low floater LEDS -starts today!
missed ETRM- try super low floater LEDS -starts today!
LEDS good quarter results just 3m Shares OS
LEDS good quarter results just 3m Shares OS
~DRYS~ now!
~DRYS~ now!
$~$_______EKSO_______$~$
$~$_______EKSO_______$~$
KOOP next LOWFLOATER 10m OS FDA neeeeewzzz
KOOP next LOWFLOATER 10m OS FDA neeeeewzzz
GEVO weeeeeeeeeeeeeeeeh
huge short-squeeze comin'? split to 10.00?
GEVO breaking out approaching 3-months record volume
? GEVO ?